Research study for subjects with Clostridium difficile infection (referred to as CDI)

IRB/UVA Tracking #
Principal Investigator
Dennis Kumral
Lakin Underwood
Contact Phone
Official Trial Title
PRISM-EXT: An Open-Label Extension of CP101 Trials
Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects with Recurrence of Clostridium difficile Infection
Study Description

The Division of Gastroenterology and Hepatology seeks adults ages 18-75 with CDI for a research study. The purpose of the study is to evaluate potential side effects and effectiveness of taking an investigational medicine (CP101) in a single dose.

Participation includes taking the study medication, at least 4 study visits and phone calls over 6 months.

All study-related insert exams, tests and study medication are provided free of charge.


$325 for completing the study